Do pathogenic neuronal autoantibodies disrupt synaptic signaling without serum positivity alone proving autoimmune encephalitis?

Neuronal autoantibody results are clinically meaningful only when interpreted in the context of syndrome, specimen type, antigen, and objective CNS findings. The central claim is well supported: several neuronal-surface antibodies can directly impair synaptic function, but serum IgG or IgA positivity alone neither diagnoses autoimmune encephalitis (AE) nor establishes antibody-mediated brain injury.

Mechanisms and biologic plausibility

• Anti-NMDAR IgG cross-links GluN1-containing receptors, causing receptor internalization and reduced excitatory synaptic transmission; these effects can reverse after antibody removal.
• GABA-receptor antibodies can reduce surface receptor expression or receptor-mediated currents, impairing inhibition.
• CASPR2 patient IgG has reduced Kv1 function, increased neuronal excitability, decreased synaptic GluA1/AMPA-receptor clusters and AMPAR currents, and caused reversible cognitive/synaptic changes after CNS infusion.
• Neuroinflammatory activation is not a universal consequence. CASPR2 passive transfer caused functional channelopathy without overt destructive inflammation; complement- and cell-mediated mechanisms appear antigen- and context-dependent. Intracellular-antigen antibodies may instead mark cytotoxic T-cell-mediated injury.

Diagnostic and causal interpretation

• AE diagnosis requires a compatible subacute neurologic syndrome, objective CNS evidence (e.g., seizures, MRI abnormalities, CSF pleocytosis), and exclusion of alternatives; serology is supportive, not determinative.
• In a nationwide cohort, only 46/148 (31%) serum-positive/CSF-negative patients met probable or definite AE/paraneoplastic neurologic syndrome criteria, whereas CSF-only positivity was associated with such diagnoses in 91%.
• Paired serum–CSF testing is preferred: CSF is generally more informative for NMDAR and GFAP, while serum may be more sensitive for LGI1 and CASPR2. Unexpected or phenotype-discordant serum findings should be confirmed by an independent/complementary assay.

Bottom line

• A positive serum neuronal IgG or IgA result is a clinical clue, not proof of AE or antibody-caused brain injury; direct pathogenicity is most credible when phenotype, objective CNS findings, CSF results, and antigen-specific biology converge.